January 16, 2009 / 7:49 AM / 10 years ago

India's Lupin gets nod for Keppra generic

MUMBAI, Jan 16 (Reuters) - Indian drug maker Lupin (LUPN.BO) said on Friday it has received final U.S. Food and Drug Administration approval to sell the generic levetiracetam tablet in multiple strengths.

The drug is prescribed for the treatment of partial seizures in adults and children with epilepsy, and had sales of about $1.2 billion for the 12 months to September 2008, the company said in a statement.

Earlier in the day, India’s Glenmark Pharmaceuticals Ltd (GLEN.BO), Aurobindo Pharma (ARBN.BO) and Orchid Chemicals (ORCD.BO) also said they had secured FDA approval to launch the generic version of UCB’s Keppra in the U.S. (Reporting by Narayanan Somasundaram; Editing by Mark Williams)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below